Welcome to the international HTA database

Showing [17102 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Health Information and Quality Authority (HIQA)	Rapid health technology assessment of continuous glucose monitoring in adults with type 1 diabetes mellitus
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC PC RCT
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	Assessment of hip protectors for users at risk of falls
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	General psychiatric management for patients with personality disorder and/or self-harm behaviour
2023	NIHR Health Technology Assessment programme	Evaluation of the Healthy Start Voucher Scheme in UK: a natural experiment using the Growing Up in Scotland record linkage study and the Infant Feeding Survey
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	Efficacy and safety of advanced hybrid closed loop systems compared with multiple daily injections or open loop systems, in adults with type 1 diabetes
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2023	Health Technology Wales (HTW)	Solution-focused assessment tools for improving the treatment of people with psychosis and schizophrenia within secondary mental health services
2023	The Regional Health Technology Assessment Centre (HTA-centrum)	[Remote patient monitoring– an overview of systematic reviews for selected diagnosis groups]
2023	NIHR Health and Social Care Delivery Program	Rapid evaluation of service innovations in health and social care: key considerations
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Update: Functioning and disability - An evidence map]
2023	NIHR Health Services and Delivery Research programme	A rapid mixed-methods evaluation of remote home monitoring models during the COVID-19 pandemic in England
2023	NIHR Health Services and Delivery Research programme	What happens after an NHS Health Check? A survey and realist review
2023	NIHR Health Services and Delivery Research programme	Identifying models of care to improve outcomes for older people with urgent care needs: a mixed methods approach to develop a system dynamics model
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Biomarkers in Alzheimer's disease
2023	NIHR Health Services and Delivery Research programme	Explanation of context, mechanisms and outcomes in adult community mental health crisis care: the MH-CREST realist evidence synthesis
2023	Belgian Health Care Knowledge Centre (KCE)	Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023	NIHR Health Services and Delivery Research programme	Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023	Norwegian Institute of Public Health (NIPH)	Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023	NIHR Health Services and Delivery Research programme	Vertical integration of general practices with acute hospitals in England: rapid impact evaluation
2023	NIHR Health Technology Assessment programme	Frenotomy with breastfeeding support versus breastfeeding support alone for infants with tongue-tie and breastfeeding difficulties: the FROSTTIE RCT
2023	NIHR Health Technology Assessment programme	Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023	NIHR Health Technology Assessment programme	Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023	NIHR Health Technology Assessment programme	A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma – the ASCOT study
2023	NIHR Health Technology Assessment programme	Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023	NIHR Health Technology Assessment programme	Helping pregnant smokers quit: a multi-centre randomised controlled trial of electronic cigarettes versus nicotine replacement therapy
2023	NIHR Health Technology Assessment programme	Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis
2023	NIHR Public Health Research (PHR) programme	A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023	NIHR Health Technology Assessment programme	Antidepressants in pregnancy: applying causal epidemiological methods to understand service-use outcomes in women and long-term neurodevelopmental outcomes in exposed children
2023	NIHR Public Health Research (PHR) programme	Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023	NIHR Health Technology Assessment programme	Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials
2023	NIHR Health Services and Delivery Research programme	Understanding what affects psychological morbidity in informal carers when providing care at home for patients at the end of life: a systematic qualitative evidence synthesis
2023	NIHR Health Technology Assessment programme	Extracorporeal carbon dioxide removal compared to ventilation alone in patients with acute hypoxaemic respiratory failure: cost-utility analysis of the REST RCT
2023	Austrian Institute for Health Technology Assessment (AIHTA)	Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (Dravet syndrome, ≥ 2 years)]
2023	National Institute for Health and Care Excellence (NICE)	Velmanase alfa for treating alpha-mannosidosis. NICE highly specialised technologies guidance 29
2023	National Institute for Health and Care Excellence (NICE)	Birch bark extract for treating epidermolysis bullosa. NICE highly specialised technologies guidance 28
2023	Ontario Health	Robotic-assisted partial nephrectomy for kidney cancer
2023	National Institute for Health and Care Excellence (NICE)	Afamelanotide for treating erythropoietic protoporphyria. NICE highly specialised technologies guidance 27
2023	Ontario Health	Robotic-assisted hysterectomy for endometrial cancer in people with obesity
2023	National Institute for Health and Care Excellence (NICE)	Lumasiran for treating primary hyperoxaluria type 1. NICE highly specialised technologies guidance 25
2023	Ontario Health	Carrier screening programs for cystic fibrosis, fragile X syndrome, hemoglobinopathies and thalassemia, and spinal muscular atrophy
2023	NIHR Health Technology Assessment programme	Tonsillectomy compared with conservative management in patients over 16 years with recurrent sore throat: the NATTINA RCT and economic evaluation
2023	National Institute for Health and Care Excellence (NICE)	Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency. NICE highly specialised technologies guidance 26
2023	NIHR Health Technology Assessment programme	A multifaceted intervention to reduce antibiotic prescribing among CHIldren with acute COugh and respiratory tract infection: the CHICO cluster RCT
2023	National Institute for Health and Care Excellence (NICE)	Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy. NICE highly specialised technologies guidance 24
2023	Scottish Health Technologies Group (SHTG)	Tumour profiling tests to guide chemotherapy decisions in early breast cancer
2023	National Institute for Health and Care Excellence (NICE)	Asfotase alfa for treating paediatric-onset hypophosphatasia. NICE highly specialised technologies guidance 23
2023	Scottish Health Technologies Group (SHTG)	Community based respiratory care services for patients with chronic respiratory conditions
2023	National Institute for Health and Care Excellence (NICE)	Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. NICE highly specialised technologies guidance 22
2023	Scottish Health Technologies Group (SHTG)	Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2023	Scottish Health Technologies Group (SHTG)	The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023	Scottish Health Technologies Group (SHTG)	The cost-effectiveness of the Scottish Hip Fracture Audit
2023	The Danish Health Technology Council (DHTC)	[Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023	Scottish Health Technologies Group (SHTG)	Outpatient parenteral antimicrobial therapy (OPAT) cost calculator
2023	Malaysian Health Technology Assessment (MaHTAS)	Far infrared therapy for arteriovenous fistulas and wound healing
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2023	Scottish Health Technologies Group (SHTG)	Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023	National Institute for Health and Care Excellence (NICE)	AposHealth for knee osteoarthritis. NICE medical technologies guidance 76
2023	Malaysian Health Technology Assessment (MaHTAS)	Digital goniometer
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Scottish Health Technologies Group (SHTG)	An assessment of the Feeling Good app
2023	Scottish Health Technologies Group (SHTG)	Consideration of selective internal radiation therapies (SIRT) for treating primary hepatocellular carcinoma (liver cancer)
2023	Scottish Health Technologies Group (SHTG)	Store-and-forward teledermatology for triage of primary care referrals
2023	Malaysian Health Technology Assessment (MaHTAS)	Ultra-portable digital x-ray system for TB screening
2023	Scottish Health Technologies Group (SHTG)	Orthotic bracing for the treatment of idiopathic scoliosis in children and young people (less than 18 years)
2023	Swiss Federal Office of Public Health (FOPH)	Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Evaluation of taking mifepristone at home during a medical abortion]
2023	NIHR Public Health Research (PHR) programme	Behavioural intervention to reduce sexually transmitted infections in people aged 16–24 years in the UK: the safetxt RCT
2023	Swiss Federal Office of Public Health (FOPH)	Folate tests for suspected folate deficiency
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those receiving chemotherapy for cancer
2023	Agency for Healthcare Research and Quality (AHRQ)	Efficacy of dental services for reducing adverse events in those undergoing insertion of implantable cardiovascular devices
2023	Swiss Federal Office of Public Health (FOPH)	Revascularisation versus optimal medical therapy (OMT) for the treatment of chronic coronary syndrome (CCS)
2023	Health Information and Quality Authority (HIQA)	Review of national public health strategies in selected countries
2023	Swiss Federal Office of Public Health (FOPH)	Calcitonin gene-related peptide antagonists for the prevention of migraine
2023	Agency for Healthcare Research and Quality (AHRQ)	Living systematic review on cannabis and other plant-based treatments for chronic pain
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ciltacabtagene autoleucel (relapsing/ refractory multiple myeloma, after at least 3 prior therapies)]
2023	Institute of Health Economics (IHE)	Optimizing MRI service capacity: review of the relationship between MRI delay and outcomes
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Belantamab mafodotin (reassessment after the deadline: multiple myeloma, at least 4 prior therapies, monotherapy)]
2023	Institute of Health Economics (IHE)	The impact of extreme heat events on health and health systems in Alberta: adaptation and mitigation strategies
2023	Health Technology Wales (HTW)	Renal denervation to treat people with resistant hypertension
2023	NIHR Health Technology Assessment programme	Impact of multiparametric MRI on staging and management of patients with suspected or confirmed ovarian cancer Short title: MR in Ovarian Cancer (MROC study)
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Etranacogene dezaparvovec (haemophilia B)]
2023	Scottish Health Technologies Group (SHTG)	Bacteriophage therapy for patients with difficult to treat bacterial infections
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023	NIHR Health Technology Assessment programme	Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial
2023	Agency for Healthcare Research and Quality (AHRQ)	Management of postpartum hypertensive disorders of pregnancy
2023	NIHR Health Services and Delivery Research programme	Involving carer advisors in evidence synthesis to improve carers’ mental health during end-of-life home care: co-production during COVID-19 remote working
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Fenfluramine (new therapeutic indication: Lennox-Gastaut syndrome, add-on therapy, ≥ 2 years)]
2023	Health Information and Quality Authority (HIQA)	Overview of multiplex antigen near-patient tests for acute respiratory infections
2023	National Institute for Health and Care Excellence (NICE)	Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 855
2023	Belgian Health Care Knowledge Centre (KCE)	Evaluation of digital medical technologies
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Emergency department overcrowding in Canada: an update
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Lonapegsomatropin (growth failure due to growth hormone deficiency, ≥ 3 to < 18 years)]
2023	National Institute for Health and Care Excellence (NICE)	Upadacitinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 856
2023	NIHR Health Services and Delivery Research programme	Reducing unplanned hospital admissions from care homes: a systematic review
2023	National Institute for Health and Care Excellence (NICE)	Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma. NICE technology appraisal guidance 857